Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Silence Therapeutics (SLNCF) Revenue (2020 - 2025)

Historic Revenue for Silence Therapeutics (SLNCF) over the last 6 years, with Q3 2025 value amounting to $159000.0.

  • Silence Therapeutics' Revenue fell 8938.58% to $159000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $25.8 million, marking a year-over-year increase of 2537.51%. This contributed to the annual value of $43.3 million for FY2024, which is 3670.64% up from last year.
  • Per Silence Therapeutics' latest filing, its Revenue stood at $159000.0 for Q3 2025, which was down 8938.58% from $224000.0 recorded in Q2 2025.
  • In the past 5 years, Silence Therapeutics' Revenue registered a high of $4350.8 billion during Q3 2021, and its lowest value of $4335.3 during Q1 2021.
  • For the 5-year period, Silence Therapeutics' Revenue averaged around $229.0 billion, with its median value being $4.0 million (2022).
  • In the last 5 years, Silence Therapeutics' Revenue skyrocketed by 16958782233177.6% in 2021 and then crashed by 9999.99% in 2022.
  • Over the past 5 years, Silence Therapeutics' Revenue (Quarter) stood at $4.6 million in 2021, then grew by 21.44% to $5.6 million in 2022, then plummeted by 53.39% to $2.6 million in 2023, then soared by 871.33% to $25.3 million in 2024, then plummeted by 99.37% to $159000.0 in 2025.
  • Its Revenue stands at $159000.0 for Q3 2025, versus $224000.0 for Q2 2025 and $142000.0 for Q1 2025.